EMBO:5年来发现的乳腺癌致癌基因ZNF703

2011-02-21 MedSci原创 MedSci原创

最近,英国和加拿大的研究人员合作研究发现,一种名为ZNF703的基因过度活跃,会导致乳腺癌。研究人员称,这是科学家5年来发现的首个乳腺癌致癌基因,对于乳腺癌的治疗极具意义。相关研究成果发表在2月18日《欧洲分子生物学学会期刊》上。 由英国剑桥大学和加拿大不列颠哥伦比亚大学的研究人员组成的研究小组,使用微阵列芯片技术,同时对大量的细胞组织样本测试,通过乳腺癌肿瘤细胞与正常健康细胞中基因活性的对比,

最近,英国和加拿大的研究人员合作研究发现,一种名为ZNF703的基因过度活跃,会导致乳腺癌。研究人员称,这是科学家5年来发现的首个乳腺癌致癌基因,对于乳腺癌的治疗极具意义。相关研究成果发表在2月18日《欧洲分子生物学学会期刊》上。

由英国剑桥大学和加拿大不列颠哥伦比亚大学的研究人员组成的研究小组,使用微阵列芯片技术,同时对大量的细胞组织样本测试,通过乳腺癌肿瘤细胞与正常健康细胞中基因活性的对比,他们发现,一种名为ZNF703的基因在雌激素受体阳性乳腺癌肿瘤中极其活跃。通过分析,研究人员判定,ZNF703是一个新的雌激素受体阳性乳腺癌驱动基因。

研究人员认为,测试ZNF703基因活性,有助于判断癌症病人肿瘤发展情况,据此可设计针对性治疗方案。而这一发现如经更大规模的研究获得证实,将为开发出新的以ZNF703基因为标靶的癌症治疗手段铺平道路。

研究论文首席作者、英国剑桥大学的卡洛斯·卡尔达斯教授指出,通过测试这种基因的活跃程度,可使医生了解标准激素疗法,如使用它莫西芬(一种抗雌激素)或者芳香酶抑制剂是否有效,从而帮助医生确认符合病人病情的针对性药物。

英国癌症研究所的莱斯利·沃尔克博士则表示,ZNF703是5年来发现的首个乳腺癌致癌基因,对于开发新的乳腺癌治疗药物十分重要,希望能藉此开发出更有效的癌症治疗手段。(生物谷Bioon.com)

生物谷推荐原文出处:

EMBO Molecular Medicine  DOI: 10.1002/emmm.201100122

ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium

Daniel G. Holland1,2, Angela Burleigh3,4, Anna Git1,2, Mae A. Goldgraben1,2, Pedro A. Perez-Mancera1,2, Suet-Feung Chin1, Antonio Hurtado1, Alejandra Bruna1,2, H. Raza Ali1,2, Wendy Greenwood1,2, Mark J. Dunning1, Shamith Samarajiwa1, Suraj Menon1, Oscar M. Rueda1,2, Andy G. Lynch1, Steven McKinney3,4, Ian O. Ellis5, Connie J. Eaves3,4, Jason S. Carroll1,2, Christina Curtis1,8, Samuel Aparicio3,4, Carlos Caldas1,2,6,7

Keywords:breast cancer;oestrogen metabolism;Luminal B;oncogene;ZNF703

The telomeric amplicon at 8p12 is common in oestrogen receptor-positive (ER+) breast cancers. Array-CGH and expression analyses of 1172 primary breast tumours revealed that ZNF703 was the single gene within the minimal amplicon and was amplified predominantly in the Luminal B subtype. Amplification was shown to correlate with increased gene and protein expression and was associated with a distinct expression signature and poor clinical outcome. ZNF703 transformed NIH 3T3 fibroblasts, behaving as a classical oncogene, and regulated proliferation in human luminal breast cancer cell lines and immortalized human mammary epithelial cells. Manipulation of ZNF703 expression in the luminal MCF7 cell line modified the effects of TGFβ on proliferation. Overexpression of ZNF703 in normal human breast epithelial cells enhanced the frequency of in vitro colony-forming cells from luminal progenitors. Taken together, these data strongly point to ZNF703 as a novel oncogene in Luminal B breast cancer.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1370748, encodeId=4ed913e074840, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373811, encodeId=0fd513e3811a9, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485545, encodeId=cdcc1485545b8, content=<a href='/topic/show?id=798c8650647' target=_blank style='color:#2F92EE;'>#致癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86506, encryptionId=798c8650647, topicName=致癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4958003576, createdName=12498dd9m13暂无昵称, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=)]
    2011-02-23 jambiya
  2. [GetPortalCommentsPageByObjectIdResponse(id=1370748, encodeId=4ed913e074840, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373811, encodeId=0fd513e3811a9, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485545, encodeId=cdcc1485545b8, content=<a href='/topic/show?id=798c8650647' target=_blank style='color:#2F92EE;'>#致癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86506, encryptionId=798c8650647, topicName=致癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4958003576, createdName=12498dd9m13暂无昵称, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1370748, encodeId=4ed913e074840, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373811, encodeId=0fd513e3811a9, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485545, encodeId=cdcc1485545b8, content=<a href='/topic/show?id=798c8650647' target=_blank style='color:#2F92EE;'>#致癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86506, encryptionId=798c8650647, topicName=致癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4958003576, createdName=12498dd9m13暂无昵称, createdTime=Wed Feb 23 13:39:00 CST 2011, time=2011-02-23, status=1, ipAttribution=)]

相关资讯

2009版乳腺癌NCCN指南(中文版)

2009_乳腺癌_NCCN_指南中文版.pdf

调查:乳腺癌三个临床实际问题探讨

  调查问题    1 乳腺癌患者是否须接受维持治疗?    2 晚期患者化疗方案的选择主要是根据临床经验还是NCCN指南?    3 靶向治疗是否有应用过度的情况,包括抗HER2治疗和血管靶向治疗?    调查对象    北京某三甲医院副主任医师A、副主任医师B、主治医师C    中国医科大学附

NEJM:辅助多西他赛治疗高危的淋巴结阴性乳腺癌

  背景 在有淋巴结阳性乳腺癌的妇女中,作为辅助疗法使用时,多西他赛、多柔比星和环磷酰胺(TAC)方案优于氟尿嘧啶、多柔比星和环磷酰胺(FAC)方案。紫杉烷类在治疗淋巴结阴性疾病中的价值还未被确定。   方法 我们将1060例患有腋淋巴结阴性乳腺癌并至少有一种复发高危因素[按照1998年圣·加仑(St.Gallen)标准]的女患者随机分为两组:一组手术后每3周接受1次TAC治疗,共6个周期;另

比较氟维司群与阿那曲唑治疗晚期乳腺癌的多中心、随机、双盲、双模拟、安慰剂对照的Ⅲ期临床试验

  报告者:中国医学科学院肿瘤医院徐兵河   时间:9 月17 日10:00~10:20   地点:16 区1 层大宴会厅   氟维司群是一种雌激素受体(ER)“灭活剂”,本研究比较了氟维司群和芳香化酶抑制剂阿那曲唑对曾接受抗激素治疗失败的中国女性晚期乳腺癌患者的疗效和安全性。    234例患者随机分入氟维司群250 mg/月(121例)或阿那曲唑1 m

乳腺癌内分泌治疗进展分享

  复旦大学肿瘤医院 周力恒 陆劲松 发自美国圣安东尼奥    一年一度的国际乳腺癌盛会——美国圣安东尼奥乳腺癌会议如期召开,本文重点介绍本次大会在乳腺癌内分泌治疗方面的部分重要报告,以期在第一时间和国内同道一起分享这些最新成果,更好地服务于患者。这些报告涉及目前临床上较为关注的一些重要课题,包括对不同第三代芳香化酶抑制剂(AI)疗效进行直接比较、探讨药物性卵巢去势联合他莫昔芬能否增效